Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

University of British Columbia

$17,500.00

Optimizing a Cellular and Protein Biomarker Discovery Pipeline for Idiopathic Pulmonary Fibrosis through Deep Immunophenotyping

FY 2022-23

Summary
Idiopathic pulmonary fibrosis (IPF), the most common type of interstitial lung disease (ILD), is a chronic, progressive and fibrotic lung disease that is characterized by interstitial inflammation, fibrosis, and destruction of the alveolar architecture. It is a debilitating lung disorder that affects thousands of Canadians and millions of individuals worldwide. The clinical signs and symptoms of IPF often overlap with common chronic obstructive lung diseases as well as subtypes of ILD, making a definitive diagnosis of IPF difficult. Despite current diagnostic guidelines that primarily rely on a combination of patient history, physical examination, and radiological data; diagnosing IPF remains a significant challenge where patients are frequently misdiagnosed and managed inappropriately with potentially harmful pharmacological therapies. As such, there is an unmet clinical need to develop blood-based diagnostic tools that transition towards laboratory-based testing for the confirmation of IPF to minimize the occurrence of misdiagnoses. In this study, we propose analyzing the immune response and comparing the immune cell composition in blood extracted from patients with IPF, chronic obstructive pulmonary disease (COPD), asthma, and other subtypes of ILD. We believe that the distinct compositions of immune cells among the patient groups can be leveraged to differentiate the diseases from one another. If successful, the analyses can result in the definition of novel blood-based protein and/or cellular markers for the diagnosis, monitoring, and/or prognosis of IPF that will ultimately improve health outcomes for millions of individuals suffering from the disease worldwide.
Program
Master's Award: Canada Graduate Scholarships
Location
British Columbia, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
486446
Name
Kuo I Chih
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Optimizing a Cellular and Protein Biomarker Discovery Pipeline for Idiopathic Pulmonary Fibrosis through Deep Immunophenotyping
Programtype2
Studentship Programs
Orgnameinp2
University of British Columbia
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Chronic Obstructive Pulmonary Disease (Copd); Cohort Studies; Fibrosis; Idiopathic Pulmonary Fibrosis (Ipf); Interstitial Lung Disease (Ild); Mass Cytometry (Cytof); Obstructive Lung Disease; Single-Cell Proteomics
Abstract
Idiopathic pulmonary fibrosis (IPF), the most common type of interstitial lung disease (ILD), is a chronic, progressive and fibrotic lung disease that is characterized by interstitial inflammation, fibrosis, and destruction of the alveolar architecture. It is a debilitating lung disorder that affects thousands of Canadians and millions of individuals worldwide. The clinical signs and symptoms of IPF often overlap with common chronic obstructive lung diseases as well as subtypes of ILD, making a definitive diagnosis of IPF difficult. Despite current diagnostic guidelines that primarily rely on a combination of patient history, physical examination, and radiological data; diagnosing IPF remains a significant challenge where patients are frequently misdiagnosed and managed inappropriately with potentially harmful pharmacological therapies. As such, there is an unmet clinical need to develop blood-based diagnostic tools that transition towards laboratory-based testing for the confirmation of IPF to minimize the occurrence of misdiagnoses. In this study, we propose analyzing the immune response and comparing the immune cell composition in blood extracted from patients with IPF, chronic obstructive pulmonary disease (COPD), asthma, and other subtypes of ILD. We believe that the distinct compositions of immune cells among the patient groups can be leveraged to differentiate the diseases from one another. If successful, the analyses can result in the definition of novel blood-based protein and/or cellular markers for the diagnosis, monitoring, and/or prognosis of IPF that will ultimately improve health outcomes for millions of individuals suffering from the disease worldwide.
Competitiondate
202212
Approvedterm2
1 yr 0 mth
Pinamesdelim
Kuo, I Chih
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~